Vantictumab
Vantictumab (OMP-18R5) is a humanized anti-FZD1/2/5/7/8 monoclonal antibody that inhibits Wnt pathway signaling and is used in research studies for the treatment of metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma.
Product Specifications
CAS Number
1345009-45-1
Stability
≥ 2 years
Purity
>98% (HPLC)
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
Wnt/beta-catenin
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog